Zelira Therapeutics (ZLDAF, $0.3) was a top loser over the last three months, falling -1 to $0.3 per share. A.I.dvisor analyzed 852 stocks in the Biotechnology Industry for the 3-month period ending March 13, 2025, and found that of them (3) exhibited an Uptrend while of them (6) demonstrated a Downtrend.